Abstract
Dose escalation can increase effectiveness of biologic treatments for plaque psoriasis, but real-world data on usage patterns and associated costs are limited. This study documents real-world patterns and additional costs of above-label use of biologics in patients with plaque psoriasis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have